Sagimet Biosciences Inc. Series A Common Stock (NASDAQ:SGMT) — Stock Price
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ:SGMT) is currently trading at $9.57 USD, up 5.63% today. Over the past 52 weeks, shares have ranged between $4.55 and $9.58. This page tracks Sagimet Biosciences Inc. Series A Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Sagimet Biosciences Inc. Series A Common market cap and net worth.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sagimet Biosciences Inc. Series A Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sagimet Biosciences Inc. Series A Common Stock Income Statement — Revenue, Profit & Earnings by Year
Sagimet Biosciences Inc. Series A Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $2.00 Million | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | $130.00K | $134.00K |
| Gross Profit | — | — | $2.00 Million | $-130.00K | $-134.00K |
| Research & Development | $39.05 Million | $38.44 Million | $19.78 Million | $24.92 Million | $19.34 Million |
| SG&A | $17.84 Million | $16.01 Million | $12.96 Million | $6.14 Million | $4.38 Million |
| Total Operating Expenses | $56.89 Million | $54.45 Million | $32.74 Million | $31.05 Million | $23.72 Million |
| Operating Income | $-56.89 Million | $-54.45 Million | $-30.74 Million | $-31.05 Million | $-23.72 Million |
| EBITDA | $-56.89 Million | $-45.57 Million | $-30.74 Million | $-31.05 Million | $-23.72 Million |
| EBIT | — | $-54.45 Million | $-61.48 Million | $-31.05 Million | $-23.72 Million |
| Interest Expense | — | — | — | — | — |
| Income Before Tax | $-51.04 Million | $-45.57 Million | $-27.88 Million | $-30.50 Million | $-24.44 Million |
| Income Tax Expense | — | — | $-2.86 Million | $-31.61 Million | $-23.75 Million |
| Net Income | $-51.04 Million | $-45.57 Million | $-27.88 Million | $-30.50 Million | $-24.44 Million |
Sagimet Biosciences Inc. Series A Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sagimet Biosciences Inc. Series A Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $116.48 Million | $160.26 Million | $96.72 Million | $33.03 Million | $59.03 Million |
| Total Current Assets | $116.40 Million | $152.77 Million | $96.65 Million | $32.79 Million | $58.66 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $78.10 Million | $75.41 Million | $19.76 Million | $32.19 Million | $0.00 |
| Net Receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $5.10 Million | $4.45 Million | $5.65 Million | $219.98 Million | $217.29 Million |
| Total Current Liabilities | $5.10 Million | $4.45 Million | $5.65 Million | $5.28 Million | $2.44 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-34.94 Million | $-75.76 Million | $-75.07 Million | $53.00K | $-56.38 Million |
| Total Stockholder Equity | $111.38 Million | $155.81 Million | $91.06 Million | $-186.95 Million | $-158.26 Million |
| Retained Earnings | $-346.35 Million | $-295.31 Million | $-249.74 Million | $-221.87 Million | $-191.37 Million |
Sagimet Biosciences Inc. Series A Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sagimet Biosciences Inc. Series A Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-45.65 Million | $-42.44 Million | $-23.77 Million | $-24.49 Million | $-21.71 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-45.65 Million | $-42.44 Million | $-23.77 Million | $-24.49 Million | $-21.71 Million |
| Investing Cash Flow | $4.56 Million | $-61.68 Million | $12.58 Million | $-32.01 Million | — |
| Financing Cash Flow | $275.00K | $104.82 Million | $86.17 Million | $-73.00K | $9.74 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $6.45 Million | $5.29 Million | $4.99 Million | $1.88 Million | $1.90 Million |
| Depreciation | — | — | — | $130.00K | $134.00K |
| Change in Cash | $-40.82 Million | $701.00K | $74.98 Million | $-56.57 Million | $-11.97 Million |
Sagimet Biosciences Inc. Series A Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Sagimet Biosciences Inc. Series A Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 11, 2026 | -0.29 | -0.40 | +27.79% |
| Nov 13, 2025 | -0.40 | -1.04 | +61.54% |
| Aug 13, 2025 | -0.32 | -0.88 | +63.64% |
| May 08, 2025 | -0.56 | -0.71 | +21.13% |
| Mar 12, 2025 | -0.50 | -0.49 | -2.04% |
| Nov 14, 2024 | -0.45 | -0.55 | +18.18% |
| Aug 15, 2024 | -0.25 | -0.50 | +50.00% |
| May 15, 2024 | -0.23 | -0.40 | +42.50% |